vigabatrin has been researched along with Seizures in 139 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T) and is used as an adjunctive therapy for adult patients with refractory complex partial seizures (rCPS)." | 9.20 | Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures. ( Hutmacher, MM; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2015) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 8.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| "The goal of our study was to examine the long-term effect of vigabatrin (VGB), a γ-aminobutyric acid aminotransferase (GABA-AT) inhibitor on clonazepam (CLO), ethosuximide (ETX) and valproate (VPA) anticonvulsive activity against pentylenetetrazole (PTZ)-induced seizures in mice." | 7.96 | Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration. ( Czuczwar, SJ; Krzyżanowski, M; Świąder, K; Świąder, MJ; Wróbel, A; Zakrocka, I; Łuszczki, JJ, 2020) |
| "Vigabatrin is indicated as adjunctive therapy for refractory focal seizures." | 7.91 | Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data. ( Chiron, C; Dulac, O; Gaillard, S; Jullien, V; Nabbout, R; Ounissi, M; Rodrigues, C, 2019) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 7.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| "To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy." | 7.85 | Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. ( Coughlin, F; Jackson, MC; Jafarpour, S; Kapur, K; Klehm, J; Loddenkemper, T; Thome-Souza, S, 2017) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 7.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| " The Food and Drug Administration-approved anti-epileptic vigabatrin has prevented HBO-induced seizures in rats up to 132 fsw." | 7.79 | Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia. ( Bodo, M; Hall, AA; Mahon, RT; Young, C, 2013) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 7.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| "Vigabatrin (VGB) has been shown to be particularly effective in the treatment of infantile spasms for those with tuberous sclerosis complex (TSC)." | 7.79 | Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. ( Bogner, M; Devinsky, O; Friedman, D; Parker-Menzer, K, 2013) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 7.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 7.74 | Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats. ( Assis, MA; Fonteles, MM; Freitas, RL; Freitas, RM; Pereira, MB; Silva, RF; Takahashi, RN, 2007) |
| "To characterize the anticonvulsant effects and types of interactions exerted by mixtures of vigabatrin (VGB) and conventional antiepileptic drugs (valproate (VPA), ethosuximide (ESM), phenobarbital (PB), and clonazepam (CZP)) in pentylenetetrazole (PTZ)-induced seizures in mice, the isobolographic analysis for three fixed-ratio combinations of 1 : 3, 1 : 1, and 3 : 1 was used." | 7.73 | Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. ( Andres, MM; Czuczwar, SJ; Luszczki, JJ; Wojcik-Cwikla, J, 2005) |
| "The effect of systemic administration of the gamma-aminobutyric acid (GABA)-transaminase inhibitor vigabatrin (VGB) on different components of convulsions was tested in the model of audiogenically kindled seizures, which consist of brainstem (running, tonus) and forebrain (clonus) elements." | 7.73 | Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats. ( Kuznetsova, GD; Shatskova, AB; van Rijn, CM; Vinogradova, LV, 2005) |
| "To describe the clinical pattern of retinal atrophy in children caused by the anticonvulsant vigabatrin." | 7.72 | Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. ( Buncic, JR; Logan, WJ; MacKeen, LD; Munn, JR; Panton, CM; Westall, CA, 2004) |
| "We present a patient with early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome) with an excellent response to chloral hydrate to draw attention to a possible role of the "old" drug in the treatment of intractable epilepsy." | 7.71 | Successful treatment of Ohtahara syndrome with chloral hydrate. ( Komárek, V; Krsek, P; Maulisová, A; Procházka, T; Sebronová, V, 2002) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 7.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain." | 7.67 | Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra. ( Bortolotto, ZA; Cavalheiro, EA; De Moraes Mello, LE; Klockgether, T; Schwarz, M; Sontag, KH; Turski, L; Turski, WA, 1986) |
| " During 1 h of bicuculline-induced seizures (1." | 7.66 | Cortical GABA turnover during bicuculline seizures in rats. ( Chapman, AG; Evans, MC, 1983) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 6.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| " The pharmacokinetic parameters of the two enantiomers have been studied after administration of a single oral 125 mg dose of the racemate to six neonates." | 6.68 | Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ( Chiron, C; d'Athis, P; Dulac, O; Dumas, C; Olive, G; Pons, G; Rey, E; Vauzelle-Kervroëdan, F, 1996) |
| "The repertoire of available and developmental therapies for epilepsy is rapidly expanding, and now includes disease-modifying vigabatrin in TSC and agents with extraordinary efficacy, fenfluramine and cenobamate." | 5.41 | Recent advances in pharmacotherapy for epilepsy. ( Klein, P; Pong, AW; Xu, KJ, 2023) |
| "Preventive treatment with vigabatrin was safe and modified the natural history of seizures in TSC, reducing the risk and severity of epilepsy." | 5.41 | Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial. ( Aronica, E; Benova, B; Borkowska, J; Curatolo, P; de Ridder, J; Domańska-Pakieła, D; Feucht, M; Głowacka-Walas, J; Hertzberg, C; Hulshof, H; Jansen, AC; Jansen, F; Jóźwiak, S; Kotulska, K; Krsek, P; Kwiatkowski, DJ; Lagae, L; Moavero, R; Nabbout, R; Riney, K; Sadowski, K; Scholl, T; Sijko, K; Weschke, B; Wojdan, K, 2021) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 5.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 5.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 5.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "The incidence of minimal, predominantly clonic seizures was not changed in any age group, but their latencies were prolonged in 18- and 25-day-old rats." | 5.31 | Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats? ( Haugvicová, R; Kubová, H; Mares, P, 2002) |
| "Vigabatrin was coupled with daily electrical kindling of the amygdala during the first week after a unilateral anteromedial cortex (AMC) lesion." | 5.31 | Vigabatrin directed against kindled seizures following cortical insult: impact on epileptogenesis and somatosensory recovery. ( Butler, SE; Hernandez, TD; Kline, AE; Montañez, S; Selwyn, AP; Suozzi, JC, 2001) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Behavioral characteristics of seizures have age-dependent features, which suggests that effective treatment of seizures may be age-specific as well." | 5.29 | Age-dependent effects of gamma-aminobutyric acid agents on flurothyl seizures. ( Moshé, SL; Ortíz, J; Ptachewich, Y; Shinnar, S; Velísek, L; Velísková, J, 1995) |
| " We conclude that vigabatrin in SSADH deficiency should be administered in a gradually increasing dosage combined with frequent evaluation of the clinical condition and the EEG." | 5.29 | Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). ( Gibson, KM; Korinthenberg, R; Lehnert, W; Matern, D, 1996) |
| "Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T) and is used as an adjunctive therapy for adult patients with refractory complex partial seizures (rCPS)." | 5.20 | Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures. ( Hutmacher, MM; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2015) |
| "Vigabatrin is a novel antiepileptic drug designed to control seizures by raising brain gamma-aminobutyric acid (GABA) concentrations." | 5.08 | Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy. ( Behar, KL; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly for the treatment of partial seizures in patients with severe epilepsies followed for years in hospital-based clinics." | 5.08 | Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. ( Arzimanoglou, AA; Dumas, C; Ghirardi, L, 1997) |
| "Vigabatrin improves seizure control as add-on therapy for refractory partial seizures and may produce therapeutic benefits in the treatment of infantile spasms." | 4.80 | Vigabatrin: a novel therapy for seizure disorders. ( Gidal, BE; Gilman, JT; Privitera, MD; Sheth, RD, 1999) |
| "Three new antiepileptic drugs--vigabatrin, gabapentin, and lamotrigine--provide alternatives in the management of older patients with refractory partial seizures." | 4.79 | Seizure control: how to use the new antiepileptic drugs in older patients. ( Haider, A; Haider, S; Tuchek, JM, 1996) |
| "Prednisolone is an effective and well-tolerated medication for treating infantile spasms in Down syndrome." | 4.12 | Response to treatment and outcomes of infantile spasms in Down syndrome. ( Allen, NM; Gorman, KM; Harvey, S; King, MD; Lynch, B; Lynch, SA; O'Regan, M; O'Rourke, D; Shahwan, A; Webb, D, 2022) |
| "We evaluated the efficacy and safety of vigabatrin in focal epilepsy associated with tuberous sclerosis complex by retrospectively reviewing patients with focal epilepsy and tuberous sclerosis complex treated with vigabatrin at a pediatric epilepsy center over an 8-year period." | 4.12 | Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures? ( Chen, L; Chen, Y; Hu, Y; Liao, J; Lin, S; Liu, G; Scheffer, IE; Su, Q; Wen, F; Yao, Y; Zhao, X, 2022) |
| " OV329, a novel drug candidate for the treatment of epilepsy and addiction, has been shown in vitro to be substantially more potent as a GABA-AT inactivator than vigabatrin, an antiseizure drug approved as an add-on therapy for adult patients with refractory complex partial seizures and monotherapy for pediatric patients with infantile spasms." | 4.02 | OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats. ( Deking, LS; During, MJ; Feja, M; Gernert, M; Kaczmarek, E; Meller, S; Silverman, RB, 2021) |
| "The goal of our study was to examine the long-term effect of vigabatrin (VGB), a γ-aminobutyric acid aminotransferase (GABA-AT) inhibitor on clonazepam (CLO), ethosuximide (ETX) and valproate (VPA) anticonvulsive activity against pentylenetetrazole (PTZ)-induced seizures in mice." | 3.96 | Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration. ( Czuczwar, SJ; Krzyżanowski, M; Świąder, K; Świąder, MJ; Wróbel, A; Zakrocka, I; Łuszczki, JJ, 2020) |
| "Vigabatrin is indicated as adjunctive therapy for refractory focal seizures." | 3.91 | Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data. ( Chiron, C; Dulac, O; Gaillard, S; Jullien, V; Nabbout, R; Ounissi, M; Rodrigues, C, 2019) |
| "Vigabatrin is recommended as first-line treatment for infantile spasms in tuberous sclerosis complex (TSC), but other indications in children with tuberous sclerosis complex are less known." | 3.88 | Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex. ( Peters, JM; Sahin, M; van der Poest Clement, EA, 2018) |
| " He had a history of neonatal seizures, had been stabilized with vigabatrin, and was seizure free without treatment for several months." | 3.88 | Catatonia Associated With a ( Amad, A; Corfiotti, C; Ferrafiat, V; Jardri, R; Leroy, A; Medjkane, F; Nguyen The Tich, S, 2018) |
| "To evaluate the efficacy and safety of vigabatrin in pediatric epilepsy." | 3.85 | Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy. ( Coughlin, F; Jackson, MC; Jafarpour, S; Kapur, K; Klehm, J; Loddenkemper, T; Thome-Souza, S, 2017) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 3.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| " The Food and Drug Administration-approved anti-epileptic vigabatrin has prevented HBO-induced seizures in rats up to 132 fsw." | 3.79 | Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia. ( Bodo, M; Hall, AA; Mahon, RT; Young, C, 2013) |
| " Vigabatrin has shown efficacy in the treatment of infantile spasms caused by tuberous sclerosis complex, but its effects on focal seizures caused by tuberous sclerosis complex have not been determined." | 3.79 | Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. ( Ko, TS; Lee, EH; Yum, MS, 2013) |
| "Vigabatrin (VGB) has been shown to be particularly effective in the treatment of infantile spasms for those with tuberous sclerosis complex (TSC)." | 3.79 | Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. ( Bogner, M; Devinsky, O; Friedman, D; Parker-Menzer, K, 2013) |
| "In our patient, seizures immediately stopped upon initiation of vigabatrin treatment, and his development and neurological examination at one year are normal." | 3.78 | Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin. ( Fluss, J; Korff, CM; Picard, F; Vulliemoz, S, 2012) |
| " We retrospectively evaluated the long-term outcome of 44 infants presenting with seizures in the first 12 months who received vigabatrin, and were followed up for at least 3." | 3.77 | Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis. ( Bombardieri, R; Curatolo, P; Cusmai, R; Moavero, R; Vigevano, F, 2011) |
| "To characterize the interactions between levetiracetam and the antiepileptic drugs gabapentin, tiagabine, and vigabatrin in suppressing pentylenetetrazole-induced clonic seizures in mice, type II isobolographic analysis was used." | 3.75 | Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. ( Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009) |
| " Isobolographic analysis was used in two mouse experimental models of epilepsy: the maximal electroshock seizure threshold test and pentylenetetrazole-induced seizures." | 3.74 | Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2008) |
| " By contrast, offspring of rats exposed to carbamazepine (which at the dose used produced low plasma concentrations) or to generalized convulsive seizures showed no clear-cut evidence of dysplasias." | 3.74 | Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias. ( Ben-Ari, Y; Depaulis, A; Jorquera, I; Manent, JB; Mazzucchelli, I; Perucca, E; Represa, A, 2007) |
| "This work was designed to study the influence of drugs during seizures and status epilepticus (SE) induced by pilocarpine and mortality in adult rats." | 3.74 | Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats. ( Assis, MA; Fonteles, MM; Freitas, RL; Freitas, RM; Pereira, MB; Silva, RF; Takahashi, RN, 2007) |
| "To characterize the anticonvulsant effects and types of interactions exerted by mixtures of vigabatrin (VGB) and conventional antiepileptic drugs (valproate (VPA), ethosuximide (ESM), phenobarbital (PB), and clonazepam (CZP)) in pentylenetetrazole (PTZ)-induced seizures in mice, the isobolographic analysis for three fixed-ratio combinations of 1 : 3, 1 : 1, and 3 : 1 was used." | 3.73 | Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. ( Andres, MM; Czuczwar, SJ; Luszczki, JJ; Wojcik-Cwikla, J, 2005) |
| "The effect of systemic administration of the gamma-aminobutyric acid (GABA)-transaminase inhibitor vigabatrin (VGB) on different components of convulsions was tested in the model of audiogenically kindled seizures, which consist of brainstem (running, tonus) and forebrain (clonus) elements." | 3.73 | Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats. ( Kuznetsova, GD; Shatskova, AB; van Rijn, CM; Vinogradova, LV, 2005) |
| "Vigabatrin, a structural analogue of gamma-aminobutyric acid (GABA), is used for the treatment of generalized and partial seizures in infants." | 3.73 | Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia. ( Coker, M; Gokben, S; Karapinar, B; Polat, M; Serdaroğlu, G; Tekgul, H; Tosun, A; Yurtsever, S, 2006) |
| " The child was treated with vigabatrin at age 6 months after an abnormal electroencephalogram but before onset of seizures." | 3.73 | Autistic regression associated with seizure onset in an infant with tuberous sclerosis. ( Bolton, PF; Clarke, A; Humphrey, A; Neville, BG, 2006) |
| "To describe the clinical pattern of retinal atrophy in children caused by the anticonvulsant vigabatrin." | 3.72 | Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children. ( Buncic, JR; Logan, WJ; MacKeen, LD; Munn, JR; Panton, CM; Westall, CA, 2004) |
| "We present a patient with early infantile epileptic encephalopathy with suppression bursts (Ohtahara syndrome) with an excellent response to chloral hydrate to draw attention to a possible role of the "old" drug in the treatment of intractable epilepsy." | 3.71 | Successful treatment of Ohtahara syndrome with chloral hydrate. ( Komárek, V; Krsek, P; Maulisová, A; Procházka, T; Sebronová, V, 2002) |
| "To determine whether the substantia nigra GABAergic anticonvulsant effects depend on GABAB receptor activation, we tested the effects of intranigral CGP 35,348 (a GABAB receptor antagonist) alone or in combination with gamma-vinyl-GABA (GVG; a GABA-transaminase inhibitor) on flurothyl seizures in rat pups and adult rats." | 3.69 | Further evidence of involvement of substantia nigra GABAB receptors in seizure suppression in developing rats. ( Garant, DS; Moshé, SL; Velísková, J; Xu, SG, 1994) |
| " In adult rats, we determined the effects on flurothyl seizures of (Z)-3-[(aminoiminomethyl)thio]prop-2-enoic acid (ZAPA, a presumed agonist of the low-affinity GABAA receptor site), bicuculline (an antagonist of the low-affinity GABAA receptor site) and gamma-vinyl-GABA (a GABA-transaminase inhibitor), infused bilaterally in anterior or posterior substantia nigra pars reticulata." | 3.69 | Developmental regulation of regional functionality of substantial nigra GABAA receptors involved in seizures. ( Moshé, SL; Nunes, ML; Velísek, L; Velísková, J, 1996) |
| "A case of a patient with medically intractable epilepsy, who developed obstructive sleep apnoea (OSA), and an increase in seizure frequency, as a consequence of weight gain following treatment with vigabatrin is described." | 3.69 | Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril). ( Bird, JM; Lambert, MV, 1997) |
| " Its anticonvulsant effects against 3-mercaptopropionic acid (MPA)-induced seizures in mice is related to the elevation of whole brain GABA concentrations: The mentioned doses of MDL 72483 which cause a decrease of GABA-T activity by 50%, produce within 5 h after dosing an increase of GABA concentration by about 3 mumol." | 3.68 | (4S)-4-amino-5,6-heptadienoic acid (MDL 72483): a potent anticonvulsant GABA-T inhibitor. ( Casara, P; Knödgen, B; Sarhan, S; Seiler, N, 1991) |
| "Vigabatrin, because of its ability to increase brain GABA concentration, acts as an anticonvulsant on convulsive epileptic seizures and increases seizures in generalized non-convulsive epilepsy." | 3.68 | Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine. ( Depaulis, A; Liu, Z; Marescaux, C; Seiler, N; Vergnes, M, 1990) |
| "The effects of intraamygdala injections of either gamma-vinyl GABA or muscimol on the behavioral and electrographic expression of stable, fully generalized, kindled seizures were assessed." | 3.67 | Microinjections of GABA agonists into the amygdala complex attenuates kindled seizure expression in the rat. ( Applegate, CD; Burchfiel, JL, 1988) |
| " The GABA-T inhibitor dose-dependently protected mice against isoniazid-induced seizures, simultaneously causing an increase in brain GABA concentrations." | 3.67 | Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice. ( Bernasconi, R; Christen, P; Hafner, T; Klein, M; Martin, P; Portet, C; Schmutz, M, 1988) |
| "Microinjection of gamma-vinyl GABA (GVG), a GABA elevating agent, into a discrete region of the deep prepiriform cortex elevated local GABA levels nearly 4-fold and exerted an anticonvulsant action against seizures induced by intravenous injection of the GABA antagonist, bicuculline, but was ineffective against seizures induced by maximal electroshock." | 3.67 | Anticonvulsant effects of GABA elevation in the deep prepiriform cortex. ( Gale, K; Pavlick, M; Piredda, S, 1987) |
| "Pilocarpine, given intraperitoneally to rats, reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain." | 3.67 | Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra. ( Bortolotto, ZA; Cavalheiro, EA; De Moraes Mello, LE; Klockgether, T; Schwarz, M; Sontag, KH; Turski, L; Turski, WA, 1986) |
| " During 1 h of bicuculline-induced seizures (1." | 3.66 | Cortical GABA turnover during bicuculline seizures in rats. ( Chapman, AG; Evans, MC, 1983) |
| "The better and earlier the seizure control, the better the child's subsequent cognitive and behavioral prognosis." | 2.82 | Overview of therapeutic options for epilepsy. ( Chiron, C; Kuchenbuch, M; Milh, M, 2022) |
| "Seventy children with newly diagnosed partial epilepsy were treated with vigabatrin (38 patients) or carbamazepine (32 patients)." | 2.69 | Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. ( Cardinali, C; Zamponi, N, 1999) |
| " The pharmacokinetic parameters of the two enantiomers have been studied after administration of a single oral 125 mg dose of the racemate to six neonates." | 2.68 | Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures. ( Chiron, C; d'Athis, P; Dulac, O; Dumas, C; Olive, G; Pons, G; Rey, E; Vauzelle-Kervroëdan, F, 1996) |
| "Vigabatrin is an antiepileptic drug licensed for use in drug-resistant epilepsy." | 2.66 | Vigabatrin add-on therapy for drug-resistant focal epilepsy. ( Bresnahan, R; Gianatsi, M; Maguire, MJ; Marson, AG; Tudur Smith, C, 2020) |
| " For vigabatrin, demonstration of similar dose-response between pediatrics and adults allowed for selection of a pediatric dose." | 2.53 | Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling. ( Bhattaram, A; Earp, JC; Florian, J; Krudys, K; Lee, JE; Lee, JY; Liu, J; Mehrotra, N; Mulugeta, Y; Sinha, V; Yu, J; Zhao, P, 2016) |
| "Vigabatrin is the treatment of choice when the underlying cause is tuberous sclerosis complex (TSC)." | 2.53 | Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy. ( Appleton, R; Iyer, A, 2016) |
| "Vigabatrin is a selective and irreversible GABA-transaminase inhibitor that greatly increases whole-brain levels of GABA." | 2.42 | Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. ( Angehagen, M; Ben-Menachem, E; Hansson, E; Rönnbäck, L, 2003) |
| " So the search for more effective drugs with minimal adverse effect profiles will continue." | 2.42 | Adverse effects of new antiepileptic drugs. ( Onat, F; Ozkara, C, 2004) |
| "Some seizure types and epilepsy syndromes appear more prone than others to exacerbation by a given drug." | 2.38 | The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin. ( Chiron, C; Dulac, O; Lortie, A; Mumford, J, 1993) |
| "4." | 2.38 | Response to vigabatrin in relation to seizure type. ( Michelucci, R; Tassinari, CA, 1989) |
| "In five cases, tonic seizures preceded spasms at a median age of 6 weeks." | 1.51 | New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. ( Bienvenu, T; Chikvinidze, G; Dulac, O; Epitashvili, N; Gataullina, S; Melikishvili, G; Tabatadze, N, 2019) |
| "Seizures are a common early presentation in infants with tuberous sclerosis complex (TSC) and can be preceded by electrographic changes on electroencephalography (EEG) before clinical seizure onset." | 1.46 | The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex. ( Jan, S; McCoy, B; Whitney, R; Zak, M, 2017) |
| "Vigabatrin is a clinically approved anti-seizure drug, which acts by increasing brain GABA levels by irreversibly inhibiting GABA-aminotransferase (GABA-T)." | 1.43 | Continuous bilateral infusion of vigabatrin into the subthalamic nucleus: Effects on seizure threshold and GABA metabolism in two rat models. ( Gernert, M; Gey, L; Löscher, W, 2016) |
| "Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32mA, 6Hz, 3s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the various drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10." | 1.40 | Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis. ( Florek-Luszczki, M; Luszczki, JJ; Wlaz, A, 2014) |
| "Vigabatrin is an inhibitor of γ-aminobutyric acid transaminase." | 1.40 | Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms. ( Karim, A; Kowalski, KG; Nielsen, JC; Patel, M; Tolbert, D; Wesche, DL, 2014) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.38 | Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. ( Filip, D; Florek-Luszczki, M; Luszczki, JJ, 2012) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 1.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "Early control of seizures has a crucial role in preventing subsequent epileptic encephalopathy, and in reducing the cognitive/behavioural consequences of seizures, but does not guarantee for a normal mental outcome in children with TSC." | 1.36 | Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. ( Bombardieri, R; Cerminara, C; Curatolo, P; Moavero, R; Pinci, M, 2010) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 1.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "Vigabatrin has been used as first-line treatment of infantile spasms." | 1.36 | MRI changes associated with vigabatrin treatment mimicking tumor progression. ( Geyer, JR; Ojemann, JG; Pruthi, S; Yang, T, 2010) |
| "Short-term outcomes for seizure cessation and electroencephalography normalization were identical between the groups." | 1.35 | Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin. ( Ben-Zeev, B; Cohen-Sadan, S; Eidlitz, T; Goldberg-Stern, H; Kivity, S; Kramer, U; Lahat, E; Nevo, Y; Sahar, E; Zeharia, A, 2009) |
| "Epileptic seizures can be difficult to recognize in infancy and childhood because the semeiology can be misleading." | 1.35 | [Epileptic seizures in childhood: from seizure type to diagnosis]. ( Chabrol, B; Hugonencq, C; Mancini, J; Milh, M; Ticus, I; Villeneuve, N, 2008) |
| "Mortality due to seizures was also evaluated." | 1.34 | Hypoxia-induced changes of seizure susceptibility in immature rats are modified by vigabatrin. ( Kubová, H; Mares, P, 2007) |
| " These results present a novel interpretation of synergistic inhibition of certain epileptic discharges using vigabatrin and another drug, and that for successful synergistic treatment of epilepsies carefully designed timed dosage regimens are essential." | 1.33 | Antiepileptic action induced by a combination of vigabatrin and tiagabine. ( Fueta, Y; Kunugita, N; Schwarz, W, 2005) |
| "In vigabatrin-treated animals, GABA synthesis was 28% lower compared to controls [p < 0." | 1.33 | Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo. ( Battaglioli, G; Behar, KL; de Graaf, RA; Martin, DL; Patel, AB, 2006) |
| "At 12h after seizure on-set, Na(+)-K(+) ATPase expression was re-enhanced in the all regions of the hippocampal complex including the dentate hilus." | 1.32 | Altered Na+-K+ ATPase immunoreactivity within GABAergic neurons in the gerbil hippocampal complex induced by spontaneous seizure and vigabatrin treatment. ( An, SJ; Hwang, IK; Kang, TC; Park, SK; Won, MH, 2004) |
| "Vigabatrin (10 microg) was injected 24 h before the first stimulation as well as 6 h before the 5th and 10th stimulation, which approximately doubled the number of stimulations required for kindling development compared with controls." | 1.32 | Bilateral microinjections of vigabatrin in the central piriform cortex retard amygdala kindling in rats. ( Ebert, U; Löscher, W; Schwabe, K, 2004) |
| "The incidence of minimal, predominantly clonic seizures was not changed in any age group, but their latencies were prolonged in 18- and 25-day-old rats." | 1.31 | Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats? ( Haugvicová, R; Kubová, H; Mares, P, 2002) |
| "Vigabatrin was coupled with daily electrical kindling of the amygdala during the first week after a unilateral anteromedial cortex (AMC) lesion." | 1.31 | Vigabatrin directed against kindled seizures following cortical insult: impact on epileptogenesis and somatosensory recovery. ( Butler, SE; Hernandez, TD; Kline, AE; Montañez, S; Selwyn, AP; Suozzi, JC, 2001) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| "Vigabatrin is a new antiepileptic medication consisting of a racemic mixture of 50% active S enantiomer and 50% inactive R enantiomer." | 1.30 | Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers. ( Mai, J; Mumford, JP; O'Mahoney, T; Olive, G; Rey, E; Tran, A, 1998) |
| "A patient with hepatic cirrhosis due to Alpers disease is described who had a significantly raised plasma alanine aminotransferase (ALT) activity of 247 U/L which returned to normal (18 U/L) shortly after commencing treatment with the anticonvulsant drug, vigabatrin." | 1.30 | Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. ( Coakley, J; Sekaninova, S; Williams, A, 1998) |
| "Limbic motor seizures in animals, analogous to complex partial seizures in humans, result in a consistent activation of the mediodorsal thalamus (MD) and, with prolonged seizures, damage to MD." | 1.30 | Mediodorsal thalamus plays a critical role in the development of limbic motor seizures. ( Cassidy, RM; Gale, K, 1998) |
| "Behavioral characteristics of seizures have age-dependent features, which suggests that effective treatment of seizures may be age-specific as well." | 1.29 | Age-dependent effects of gamma-aminobutyric acid agents on flurothyl seizures. ( Moshé, SL; Ortíz, J; Ptachewich, Y; Shinnar, S; Velísek, L; Velísková, J, 1995) |
| "PTZ-induced convulsions were partly antagonized by the GVG treatment." | 1.29 | The significance of extracellular GABA in the substantia nigra of the rat during seizures and anticonvulsant treatments. ( Sayin, U; Timmerman, W; Westerink, BH, 1995) |
| "Kainic acid (KA)-induced convulsions are accompanied by histopathological changes that are most prominent in the temporal lobe structures." | 1.29 | Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. ( Halonen, T; Kotti, T; Miettinen, R; Riekkinen, PJ; Toppinen, A; Tuunanen, J, 1995) |
| " We conclude that vigabatrin in SSADH deficiency should be administered in a gradually increasing dosage combined with frequent evaluation of the clinical condition and the EEG." | 1.29 | Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA). ( Gibson, KM; Korinthenberg, R; Lehnert, W; Matern, D, 1996) |
| " In the present study, we determined, in rat pups, the effect of nigral infusions of gamma-vinyl-GABA (GVG) on clonic-tonic seizures induced by flurothyl, generated a dose-response curve of the GVG effect and investigated the possible role of the nigral GABAA receptor in mediating the GVG effect." | 1.28 | Is the anticonvulsant effect of substantia nigra infusion of gamma-vinyl-GABA (GVG) mediated by the GABAA receptor in rat pups? ( Moshé, SL; Sperber, EF; Xu, SG, 1991) |
| "2." | 1.28 | Cerebrospinal fluid GABA and seizure control with vigabatrin. ( Halonen, T; Pitkanen, A; Riekkinen, PJ; Sivenius, J; Ylinen, A, 1989) |
| "Seizures were markedly suppressed in animals with bilateral destruction of the SN but not in animals in which the SN was spared bilaterally." | 1.27 | Evidence implicating substantia nigra in regulation of kindled seizure threshold. ( Galloway, MT; McNamara, JO; Rigsbee, LC; Shin, C, 1984) |
| "Amygdaloid kindled generalized convulsion was reversibly blocked despite continued afterdischarge generation by amygdaloid stimulation for about 60 h following intracerebral administration of gabaculine, a GABA-transaminase inhibitor, into the substantia innominata (SI) ipsilateral to the side of amygdaloid kindling." | 1.27 | Reversible suppression of amygdaloid kindled convulsion following unilateral gabaculine injection into the substantia innominata. ( Okamoto, M; Wada, JA, 1984) |
| "This result indicates that while the seizure-suppressant effect of intranigral GVG requires alpha 2-mediated NE neurotransmission, the mechanism of this anticonvulsant action is not by increasing NE neuronal activity." | 1.27 | Anticonvulsant action of intranigral gamma-vinyl-GABA: role of nonadrenergic neurotransmission. ( Bonhaus, DW; McNamara, JO, 1988) |
| "Thus, the seizure-facilitating nigral efferents may be subject to inhibition by both GABA and opiates and may normally be driven by substance P." | 1.27 | Role of the substantia nigra in GABA-mediated anticonvulsant actions. ( Gale, K, 1986) |
| "PTZ seizures were prevented by GVG injections in the anterior thalamus, the caudal hypothalamus, the superior colliculus, cerebellar nuclei, and in a large area of the medial medullary, pontine, and mesencephalic tegmentum encompassing the vestibular nuclei, the reticular formation, and portions of the central gray." | 1.27 | Functional anatomy of pentylenetetrazol and electroshock seizures in the rat brainstem. ( Ferrendelli, JA; McKeon, AC; Miller, JW, 1987) |
| "Both types of seizures were prevented by injections into both of the above brain regions." | 1.27 | Anterior thalamus and substantia nigra: two distinct structures mediating experimental generalized seizures. ( Ferrendelli, JA; McKeon, AC; Mirski, MA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (19.42) | 18.7374 |
| 1990's | 37 (26.62) | 18.2507 |
| 2000's | 35 (25.18) | 29.6817 |
| 2010's | 28 (20.14) | 24.3611 |
| 2020's | 12 (8.63) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, YC | 1 |
| Zhao, LX | 3 |
| Kim, TH | 1 |
| Je, SM | 1 |
| Kim, EK | 3 |
| Choi, H | 1 |
| Chae, WG | 1 |
| Park, M | 1 |
| Choi, J | 3 |
| Jahng, Y | 3 |
| Lee, ES | 3 |
| Feja, M | 1 |
| Meller, S | 1 |
| Deking, LS | 1 |
| Kaczmarek, E | 1 |
| During, MJ | 1 |
| Silverman, RB | 1 |
| Gernert, M | 3 |
| Harvey, S | 1 |
| Allen, NM | 1 |
| King, MD | 1 |
| Lynch, B | 1 |
| Lynch, SA | 1 |
| O'Regan, M | 1 |
| O'Rourke, D | 1 |
| Shahwan, A | 1 |
| Webb, D | 1 |
| Gorman, KM | 1 |
| Lin, S | 1 |
| Liao, J | 1 |
| Zhao, X | 1 |
| Hu, Y | 1 |
| Chen, L | 1 |
| Chen, Y | 1 |
| Liu, G | 1 |
| Yao, Y | 1 |
| Su, Q | 1 |
| Scheffer, IE | 1 |
| Wen, F | 1 |
| Kuchenbuch, M | 2 |
| Chiron, C | 5 |
| Milh, M | 2 |
| de Saint Martin, A | 1 |
| Napuri, S | 1 |
| Nguyen, S | 1 |
| Pong, AW | 1 |
| Xu, KJ | 1 |
| Klein, P | 1 |
| Madaan, P | 1 |
| Negi, S | 1 |
| Sharma, R | 1 |
| Kaur, A | 1 |
| Sahu, JK | 1 |
| Świąder, MJ | 1 |
| Świąder, K | 1 |
| Zakrocka, I | 1 |
| Krzyżanowski, M | 1 |
| Wróbel, A | 1 |
| Łuszczki, JJ | 1 |
| Czuczwar, SJ | 5 |
| Fortini, S | 1 |
| Valenzuela, GR | 1 |
| Fasulo, L | 1 |
| Caraballo, R | 1 |
| Uematsu, M | 1 |
| Numata-Uematsu, Y | 1 |
| Aihara, Y | 1 |
| Kobayashi, T | 1 |
| Fujikawa, M | 1 |
| Togashi, N | 1 |
| Shiihara, T | 1 |
| Ohashi, K | 1 |
| Hattori, A | 1 |
| Saitoh, S | 1 |
| Kure, S | 1 |
| Bresnahan, R | 1 |
| Gianatsi, M | 1 |
| Maguire, MJ | 1 |
| Tudur Smith, C | 1 |
| Marson, AG | 1 |
| Kotulska, K | 1 |
| Kwiatkowski, DJ | 1 |
| Curatolo, P | 5 |
| Weschke, B | 1 |
| Riney, K | 1 |
| Jansen, F | 1 |
| Feucht, M | 1 |
| Krsek, P | 2 |
| Nabbout, R | 3 |
| Jansen, AC | 1 |
| Wojdan, K | 1 |
| Sijko, K | 1 |
| Głowacka-Walas, J | 1 |
| Borkowska, J | 1 |
| Sadowski, K | 1 |
| Domańska-Pakieła, D | 1 |
| Moavero, R | 3 |
| Hertzberg, C | 1 |
| Hulshof, H | 1 |
| Scholl, T | 1 |
| Benova, B | 1 |
| Aronica, E | 1 |
| de Ridder, J | 1 |
| Lagae, L | 1 |
| Jóźwiak, S | 1 |
| Whitney, R | 1 |
| Jan, S | 1 |
| Zak, M | 1 |
| McCoy, B | 1 |
| Jackson, MC | 1 |
| Jafarpour, S | 1 |
| Klehm, J | 1 |
| Thome-Souza, S | 1 |
| Coughlin, F | 1 |
| Kapur, K | 1 |
| Loddenkemper, T | 1 |
| van der Poest Clement, EA | 1 |
| Sahin, M | 1 |
| Peters, JM | 1 |
| Leroy, A | 1 |
| Corfiotti, C | 1 |
| Nguyen The Tich, S | 1 |
| Ferrafiat, V | 1 |
| Amad, A | 1 |
| Jardri, R | 1 |
| Medjkane, F | 1 |
| Rodrigues, C | 1 |
| Ounissi, M | 1 |
| Dulac, O | 4 |
| Gaillard, S | 1 |
| Jullien, V | 1 |
| Melikishvili, G | 1 |
| Epitashvili, N | 1 |
| Tabatadze, N | 1 |
| Chikvinidze, G | 1 |
| Bienvenu, T | 1 |
| Gataullina, S | 1 |
| Zhang, B | 1 |
| McDaniel, SS | 1 |
| Rensing, NR | 1 |
| Wong, M | 1 |
| Hall, AA | 1 |
| Young, C | 1 |
| Bodo, M | 1 |
| Mahon, RT | 1 |
| Romaniello, R | 1 |
| Zucca, C | 1 |
| Tenderini, E | 1 |
| Arrigoni, F | 1 |
| Ragona, F | 1 |
| Zorzi, G | 1 |
| Bassi, MT | 1 |
| Borgatti, R | 1 |
| Florek-Luszczki, M | 2 |
| Wlaz, A | 1 |
| Luszczki, JJ | 6 |
| Jones, K | 1 |
| Snead, OC | 1 |
| Boyd, J | 1 |
| Go, C | 1 |
| Nielsen, JC | 2 |
| Hutmacher, MM | 1 |
| Wesche, DL | 2 |
| Tolbert, D | 2 |
| Patel, M | 2 |
| Kowalski, KG | 2 |
| Karim, A | 1 |
| Gey, L | 2 |
| Löscher, W | 3 |
| Mehrotra, N | 1 |
| Bhattaram, A | 1 |
| Earp, JC | 1 |
| Florian, J | 1 |
| Krudys, K | 1 |
| Lee, JE | 1 |
| Lee, JY | 1 |
| Liu, J | 1 |
| Mulugeta, Y | 1 |
| Yu, J | 1 |
| Zhao, P | 1 |
| Sinha, V | 1 |
| Iyer, A | 1 |
| Appleton, R | 1 |
| Zelnik, N | 1 |
| Isler, N | 1 |
| Goez, H | 1 |
| Shiffer, M | 1 |
| David, M | 1 |
| Shahar, E | 1 |
| Ratnaraj, N | 2 |
| Patsalos, PN | 2 |
| Dudra-Jastrzebska, M | 1 |
| Andres-Mach, MM | 1 |
| Sielski, M | 1 |
| Cohen-Sadan, S | 1 |
| Kramer, U | 1 |
| Ben-Zeev, B | 1 |
| Lahat, E | 1 |
| Sahar, E | 1 |
| Nevo, Y | 1 |
| Eidlitz, T | 1 |
| Zeharia, A | 1 |
| Kivity, S | 1 |
| Goldberg-Stern, H | 1 |
| Bombardieri, R | 2 |
| Pinci, M | 1 |
| Cerminara, C | 1 |
| Kubová, H | 4 |
| Mares, P | 4 |
| Yang, T | 1 |
| Pruthi, S | 1 |
| Geyer, JR | 1 |
| Ojemann, JG | 1 |
| Nandhagopal, R | 1 |
| Filip, D | 1 |
| Cusmai, R | 1 |
| Vigevano, F | 1 |
| Bröer, S | 1 |
| Backofen-Wehrhahn, B | 1 |
| Bankstahl, M | 1 |
| Nieoczym, D | 1 |
| Socała, K | 1 |
| Wlaź, P | 1 |
| Yum, MS | 1 |
| Lee, EH | 1 |
| Ko, TS | 1 |
| Korff, CM | 1 |
| Vulliemoz, S | 1 |
| Picard, F | 1 |
| Fluss, J | 1 |
| Friedman, D | 1 |
| Bogner, M | 1 |
| Parker-Menzer, K | 1 |
| Devinsky, O | 1 |
| Haugvicová, R | 1 |
| Sebronová, V | 1 |
| Procházka, T | 1 |
| Maulisová, A | 1 |
| Komárek, V | 1 |
| Kang, TC | 5 |
| An, SJ | 4 |
| Park, SK | 4 |
| Hwang, IK | 4 |
| Bae, JC | 1 |
| Won, MH | 5 |
| Angehagen, M | 1 |
| Ben-Menachem, E | 1 |
| Rönnbäck, L | 1 |
| Hansson, E | 1 |
| Choi, SY | 3 |
| Kwon, OS | 2 |
| Sills, GJ | 1 |
| Moon, YS | 2 |
| Basnet, A | 2 |
| Park, JG | 2 |
| Kim, DO | 1 |
| Jeong, TC | 2 |
| Best, JL | 1 |
| Acheson, JF | 2 |
| Onat, F | 1 |
| Ozkara, C | 1 |
| Choi, HJ | 1 |
| Kim, DM | 1 |
| Buncic, JR | 1 |
| Westall, CA | 1 |
| Panton, CM | 1 |
| Munn, JR | 1 |
| MacKeen, LD | 1 |
| Logan, WJ | 1 |
| Schwabe, K | 1 |
| Ebert, U | 1 |
| Wojcik-Cwikla, J | 1 |
| Andres, MM | 1 |
| Fueta, Y | 1 |
| Kunugita, N | 1 |
| Schwarz, W | 1 |
| Vinogradova, LV | 1 |
| Kuznetsova, GD | 1 |
| Shatskova, AB | 1 |
| van Rijn, CM | 1 |
| Kwak, SE | 1 |
| Kim, JE | 1 |
| Kim, DS | 1 |
| Choi, HC | 1 |
| Kim, YI | 1 |
| Song, HK | 1 |
| Patel, AB | 1 |
| de Graaf, RA | 1 |
| Martin, DL | 1 |
| Battaglioli, G | 1 |
| Behar, KL | 2 |
| Tekgul, H | 1 |
| Serdaroğlu, G | 1 |
| Karapinar, B | 1 |
| Polat, M | 1 |
| Yurtsever, S | 1 |
| Tosun, A | 1 |
| Coker, M | 1 |
| Gokben, S | 1 |
| Kjellström, U | 1 |
| Kjellström, S | 1 |
| Bruun, A | 1 |
| Andréasson, S | 1 |
| Ponjavic, V | 1 |
| Humphrey, A | 1 |
| Neville, BG | 1 |
| Clarke, A | 1 |
| Bolton, PF | 1 |
| Manent, JB | 1 |
| Jorquera, I | 1 |
| Mazzucchelli, I | 1 |
| Depaulis, A | 2 |
| Perucca, E | 1 |
| Ben-Ari, Y | 1 |
| Represa, A | 1 |
| Pereira, MB | 1 |
| Freitas, RL | 1 |
| Assis, MA | 1 |
| Silva, RF | 1 |
| Fonteles, MM | 1 |
| Freitas, RM | 1 |
| Takahashi, RN | 1 |
| Ticus, I | 1 |
| Villeneuve, N | 1 |
| Hugonencq, C | 1 |
| Mancini, J | 1 |
| Chabrol, B | 1 |
| Iadarola, MJ | 2 |
| Gale, K | 5 |
| McNamara, JO | 2 |
| Galloway, MT | 1 |
| Rigsbee, LC | 1 |
| Shin, C | 1 |
| Sarhan, S | 2 |
| Kolb, M | 1 |
| Seiler, N | 3 |
| Okamoto, M | 1 |
| Wada, JA | 1 |
| Le Gal La Salle, G | 2 |
| Kaijima, M | 2 |
| Feldblum, S | 1 |
| Meldrum, BS | 1 |
| Murugaiah, K | 1 |
| Chapman, AG | 1 |
| Evans, MC | 1 |
| Jobe, PC | 1 |
| Graham, LT | 1 |
| Ray, TB | 1 |
| Mims, ME | 1 |
| Kendall, DA | 1 |
| Fox, DA | 1 |
| Enna, SJ | 1 |
| Kalichman, MW | 1 |
| Livingston, KE | 1 |
| Burnham, WM | 1 |
| Velísek, L | 2 |
| Velísková, J | 3 |
| Ptachewich, Y | 1 |
| Ortíz, J | 1 |
| Shinnar, S | 1 |
| Moshé, SL | 6 |
| Gibson, KM | 2 |
| Jakobs, C | 1 |
| Ogier, H | 1 |
| Hagenfeldt, L | 1 |
| Eeg-Olofsson, KE | 1 |
| Eeg-Olofsson, O | 1 |
| Aksu, F | 1 |
| Weber, HP | 1 |
| Rossier, E | 1 |
| Vollmer, B | 1 |
| Sayin, U | 2 |
| Timmerman, W | 1 |
| Westerink, BH | 1 |
| Rahbeeni, Z | 1 |
| Ozand, PT | 1 |
| Rashed, M | 1 |
| Gascon, GG | 1 |
| al Nasser, M | 1 |
| al Odaib, A | 1 |
| Amoudi, M | 1 |
| Nester, M | 1 |
| al Garawi, S | 1 |
| Brismar, J | 1 |
| Garant, DS | 3 |
| Xu, SG | 4 |
| Sälke-Kellermann, A | 1 |
| Baier, H | 1 |
| Rambeck, B | 1 |
| Boenigk, HE | 1 |
| Wolf, P | 2 |
| Cengiz, S | 1 |
| Altug, T | 1 |
| de Romanis, F | 1 |
| Sopranzi, N | 1 |
| Lhoir, A | 1 |
| Sperber, EF | 3 |
| Lortie, A | 1 |
| Mumford, J | 1 |
| Halonen, T | 2 |
| Kotti, T | 1 |
| Tuunanen, J | 1 |
| Toppinen, A | 1 |
| Miettinen, R | 1 |
| Riekkinen, PJ | 2 |
| Matern, D | 1 |
| Lehnert, W | 1 |
| Korinthenberg, R | 1 |
| Haider, A | 1 |
| Tuchek, JM | 1 |
| Haider, S | 1 |
| Bourgeois, B | 1 |
| Nunes, ML | 1 |
| Petroff, OA | 1 |
| Mattson, RH | 1 |
| Rothman, DL | 1 |
| Vauzelle-Kervroëdan, F | 1 |
| Rey, E | 2 |
| Pons, G | 1 |
| d'Athis, P | 1 |
| Dumas, C | 2 |
| Olive, G | 2 |
| Marciani, MG | 1 |
| Stanzione, P | 1 |
| Maschio, M | 1 |
| Spanedda, F | 1 |
| Bassetti, MA | 1 |
| Mattia, D | 1 |
| Bernardi, G | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Arzimanoglou, AA | 1 |
| Ghirardi, L | 1 |
| Lambert, MV | 1 |
| Bird, JM | 1 |
| Tran, A | 1 |
| O'Mahoney, T | 1 |
| Mai, J | 1 |
| Mumford, JP | 1 |
| Lücke, A | 1 |
| Musshoff, U | 1 |
| Köhling, R | 1 |
| Osterfeld, M | 1 |
| Mayer, T | 1 |
| Schütte, W | 1 |
| Speckmann, EJ | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| Engelborghs, S | 1 |
| Pickut, BA | 1 |
| D'Hooge, R | 1 |
| Wiechert, P | 1 |
| Haegele, K | 1 |
| De Deyn, PP | 1 |
| Williams, A | 1 |
| Sekaninova, S | 1 |
| Coakley, J | 1 |
| Cassidy, RM | 1 |
| Zamponi, N | 1 |
| Cardinali, C | 1 |
| Gidal, BE | 1 |
| Privitera, MD | 1 |
| Sheth, RD | 1 |
| Gilman, JT | 1 |
| Raol, YH | 1 |
| Meti, BL | 1 |
| Stuchlík, A | 1 |
| Montañez, S | 1 |
| Kline, AE | 1 |
| Selwyn, AP | 1 |
| Suozzi, JC | 1 |
| Butler, SE | 1 |
| Hernandez, TD | 1 |
| Stephenson, JB | 1 |
| Casara, P | 1 |
| Knödgen, B | 1 |
| Liu, Z | 1 |
| Marescaux, C | 1 |
| Vergnes, M | 1 |
| Michelucci, R | 1 |
| Tassinari, CA | 1 |
| Rimmer, EM | 1 |
| Richens, A | 1 |
| Ylinen, A | 1 |
| Sivenius, J | 1 |
| Pitkanen, A | 1 |
| Bonhaus, DW | 1 |
| Hammond, EJ | 2 |
| Wilder, BJ | 2 |
| Applegate, CD | 1 |
| Burchfiel, JL | 1 |
| Bernasconi, R | 1 |
| Klein, M | 1 |
| Martin, P | 1 |
| Christen, P | 1 |
| Hafner, T | 1 |
| Portet, C | 1 |
| Schmutz, M | 1 |
| Miller, JW | 1 |
| McKeon, AC | 2 |
| Ferrendelli, JA | 3 |
| Piredda, S | 1 |
| Pavlick, M | 1 |
| Mirski, MA | 2 |
| Toussi, HR | 1 |
| Schatz, RA | 1 |
| Waszczak, BL | 1 |
| Turski, L | 1 |
| Cavalheiro, EA | 1 |
| Schwarz, M | 1 |
| Turski, WA | 1 |
| De Moraes Mello, LE | 1 |
| Bortolotto, ZA | 1 |
| Klockgether, T | 1 |
| Sontag, KH | 1 |
| Tanaka, T | 1 |
| Yonemasu, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| Pharmacotoxicology of Trichloroethylene Metabolites: Short-term Effect of DCA on in Vivo Tyrosine Catabolism and MAAI Expression[NCT00865514] | 2 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Difficulty in obtaining the solution from the compounding pharmacies caused a two year delay in start-up; the funding ended prior to study completion.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 reviews available for vigabatrin and Seizures
| Article | Year |
|---|---|
Overview of therapeutic options for epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Prognosis; Seizures; Spasms, | 2022 |
Tuberous sclerosis complex and epilepsy in infancy: prevention and early diagnosis.
Topics: Anticonvulsants; Child; Early Diagnosis; Epilepsy; Humans; Infant; Infant, Newborn; Seizures; Tubero | 2022 |
Recent advances in pharmacotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Child; Epilepsies, Myoclonic; Epilepsies, Partial; Epilepsy; Fenfluramine; H | 2023 |
Vigabatrin add-on therapy for drug-resistant focal epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dizziness; Drug Resistant Epilepsy; Drug Therapy, Combina | 2020 |
Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Cannabidiol; Humans; MTOR Inhibitors; Seizures; Tuberous Sclerosis; Vigabatrin | 2021 |
Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
Topics: Adalimumab; Adolescent; Adolescent Development; Adult; Age Factors; Anti-HIV Agents; Anti-Inflammato | 2016 |
Improving Outcomes in Infantile Spasms: Role of Pharmacotherapy.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Humans; Infant; Pyridoxine; S | 2016 |
Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate.
Topics: Anticonvulsants; Fructose; Neuroprotective Agents; Nipecotic Acids; Seizures; Tiagabine; Topiramate; | 2003 |
Pre-clinical studies with the GABAergic compounds vigabatrin and tiagabine.
Topics: Animals; Anticonvulsants; GABA Agonists; Humans; Nipecotic Acids; Receptors, GABA; Seizures; Tiagabi | 2003 |
Adverse effects of new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Felbamate; Humans; Phenylcarbamat | 2004 |
Cellular compartments of GABA in brain and their relationship to anticonvulsant activity.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Aminooxyacetic Acid; Animals; Anticonvulsants; Brain; | 1981 |
The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin.
Topics: Aminocaproates; Anticonvulsants; Humans; Infant; Recurrence; Seizures; Vigabatrin | 1993 |
Seizure control: how to use the new antiepileptic drugs in older patients.
Topics: Acetates; Age Factors; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions | 1996 |
Clinical use of drugs useful in the treatment of atonic seizures.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam; Epilepsy, Genera | 1995 |
Vigabatrin: a novel therapy for seizure disorders.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Humans; Seizures; Vigabatrin | 1999 |
Response to vigabatrin in relation to seizure type.
Topics: Aminocaproates; Anticonvulsants; Humans; Seizures; Vigabatrin | 1989 |
Gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Behavior, Animal; beta-Alanine; | 1985 |
7 trials available for vigabatrin and Seizures
| Article | Year |
|---|---|
Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Electroencephalography; Epilepsy; Female; Humans; Infant; | 2021 |
Population dose-response analysis of daily seizure count following vigabatrin therapy in adult and pediatric patients with refractory complex partial seizures.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Femal | 2015 |
[Gamma-vinyl-GABA: first experiences in Italy. II].
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; | 1994 |
Human brain gamma-aminobutyric acid levels and seizure control following initiation of vigabatrin therapy.
Topics: Adult; Anticonvulsants; Epilepsy, Complex Partial; Female; gamma-Aminobutyric Acid; Humans; Male; Mi | 1996 |
Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures.
Topics: Anticonvulsants; Area Under Curve; gamma-Aminobutyric Acid; Gas Chromatography-Mass Spectrometry; Ha | 1996 |
Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Epilepsies, Partial; Female; gamma-Aminobutyric Aci | 1997 |
Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children.
Topics: Administration, Oral; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Epilepsies, Partial; | 1999 |
115 other studies available for vigabatrin and Seizures
| Article | Year |
|---|---|
Design and synthesis of anticonvulsive agents as gamma-vinyl GABA-based potential dual acting prodrugs and their biological activities.
Topics: Animals; Anticonvulsants; Bicuculline; Drug Design; Mice; Pentylenetetrazole; Picrotoxin; Prodrugs; | 2000 |
OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Kindling, Neu | 2021 |
Response to treatment and outcomes of infantile spasms in Down syndrome.
Topics: Adult; Anticonvulsants; Child; Down Syndrome; Humans; Infant; Prednisolone; Seizures; Spasm; Spasms, | 2022 |
Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures?
Topics: Anticonvulsants; Child; Epilepsies, Partial; Humans; Infant; Retrospective Studies; Seizures; Treatm | 2022 |
X-Linked ALG13 Gene Variant as a Cause of Epileptic Encephalopathy in Girls.
Topics: Brain; Exome; Female; Genetic Predisposition to Disease; Genetic Variation; Humans; India; Infant; M | 2019 |
Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Brain; Clonazepam; Disease Models, Animal; D | 2020 |
West syndrome: A study of 26 patients receiving short-term therapy.
Topics: Adrenocorticotropic Hormone; Child; Electroencephalography; Female; Humans; Infant; Male; Seizures; | 2021 |
Behavioral problems and family distress in tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Checklist; Child; Child, Preschool; Family Relations; Female; Humans; M | 2020 |
The Utility of Surveillance Electroencephalography to Guide Early Antiepileptic Drug Therapy in Infants With Tuberous Sclerosis Complex.
Topics: Anticonvulsants; Brain; Electroencephalography; Female; Humans; Infant; Prospective Studies; Seizure | 2017 |
Effect of vigabatrin on seizure control and safety profile in different subgroups of children with epilepsy.
Topics: Anticonvulsants; Brain; Electroencephalography; Epilepsy; Female; Humans; Infant; Male; Retrospectiv | 2017 |
Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex.
Topics: Adolescent; Anticonvulsants; Brain; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Hu | 2018 |
Catatonia Associated With a
Topics: Anticonvulsants; Catatonia; Child, Preschool; Humans; Lorazepam; Mutation; NAV1.2 Voltage-Gated Sodi | 2018 |
Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data.
Topics: Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Infant; | 2019 |
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Astrocytes; Brain; Cell Proliferation; Cells, Cultured; Disease Models, An | 2013 |
Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia.
Topics: Animals; Anticonvulsants; Decompression; Decompression Sickness; Disease Models, Animal; Diving; Hea | 2013 |
A novel mutation in STXBP1 gene in a child with epileptic encephalopathy and an atypical electroclinical pattern.
Topics: Amino Acid Sequence; Anticonvulsants; Brain; Child, Preschool; Electroencephalography; Humans; Infan | 2014 |
Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Drug Combinatio | 2014 |
Adrenocorticotropic hormone versus prednisolone in the treatment of infantile spasms post vigabatrin failure.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Cohort Studies; Female; Humans; Infant; Male; Predniso | 2015 |
Population pharmacokinetics analysis of vigabatrin in adults and children with epilepsy and children with infantile spasms.
Topics: Adult; Body Weight; Child; Child, Preschool; Enzyme Inhibitors; Epilepsy; Female; gamma-Aminobutyric | 2014 |
Continuous bilateral infusion of vigabatrin into the subthalamic nucleus: Effects on seizure threshold and GABA metabolism in two rat models.
Topics: Animals; Basal Ganglia; Disease Models, Animal; Electric Stimulation; Female; gamma-Aminobutyric Aci | 2016 |
Vigabatrin, lamotrigine, topiramate and serum carnitine levels.
Topics: Adolescent; Anticonvulsants; Carnitine; Child; Child, Preschool; Female; Fructose; Humans; Infant; L | 2008 |
Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Disease Mode | 2008 |
Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug I | 2009 |
Multicenter long-term follow-up of children with idiopathic West syndrome: ACTH versus vigabatrin.
Topics: Adolescent; Adrenocorticotropic Hormone; Age of Onset; Anticonvulsants; Brain; Child; Child Developm | 2009 |
Early control of seizures improves long-term outcome in children with tuberous sclerosis complex.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Electroencephalography; F | 2010 |
Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Disease Models, Animal; E | 2010 |
MRI changes associated with vigabatrin treatment mimicking tumor progression.
Topics: Anticonvulsants; Brain Neoplasms; Disease Progression; Female; Humans; Infant; Oligodendroglioma; Se | 2010 |
Coexistence of cerebral tubers with neurocysticercosis.
Topics: Anticonvulsants; Brain Diseases; Child; Humans; Incidental Findings; Male; Neurocysticercosis; Seizu | 2010 |
Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Confidence Intervals; Cyclohexanecarboxylic Ac | 2012 |
Long-term neurological outcome in children with early-onset epilepsy associated with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition Disorders; Developmental Disabilitie | 2011 |
Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Epilepsy; Female; Microinjections; Rats; Rat | 2012 |
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Cyclohexanecarboxylic Acids; Disease Models, A | 2012 |
Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures.
Topics: Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Intellectual Disa | 2013 |
Ohtahara syndrome or early-onset West syndrome? A case with overlapping features and favorable response to vigabatrin.
Topics: Anticonvulsants; Carbamazepine; Drug Resistance; Electroencephalography; Humans; Infant; Male; Neuro | 2012 |
Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex.
Topics: Anticonvulsants; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; Seizures; Treatmen | 2013 |
Does vigabatrin possess an anticonvulsant action against pentylenetetrazol-induced seizures in developing rats?
Topics: Animals; Animals, Newborn; Anticonvulsants; Convulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clon | 2002 |
Successful treatment of Ohtahara syndrome with chloral hydrate.
Topics: Anticonvulsants; Chloral Hydrate; Drug Therapy, Combination; Electroencephalography; Female; Humans; | 2002 |
Changed vesicular GABA transporter immunoreactivity in the gerbil hippocampus following spontaneous seizure and vigabatrin administration.
Topics: Animals; Anticonvulsants; Carrier Proteins; GABA Plasma Membrane Transport Proteins; Gerbillinae; Hi | 2003 |
Effect of vigabatrin on glutamate dehydrogenase in the hippocampus of seizure prone gerbils.
Topics: Animals; Enzyme Inhibitors; Gerbillinae; Glutamate Dehydrogenase; Hippocampus; Seizures; Vigabatrin | 2003 |
Vigabatrin inhibits pyridoxine-5'-phosphate oxidase, not pyridoxal kinase in the hippocampus of seizure prone gerbils.
Topics: Animals; Blotting, Western; Densitometry; Enzyme Inhibitors; Gerbillinae; Hippocampus; Immunohistoch | 2004 |
Design, synthesis and anticonvulsive activities of potential prodrugs linked by two-carbon chain.
Topics: Animals; Anticonvulsants; Carbon; Convulsants; Dimerization; Drug Design; Electroshock; gamma-Aminob | 2003 |
Altered Na+-K+ ATPase immunoreactivity within GABAergic neurons in the gerbil hippocampal complex induced by spontaneous seizure and vigabatrin treatment.
Topics: Animals; gamma-Aminobutyric Acid; Gerbillinae; Hippocampus; Neurons; Seizures; Sodium-Potassium-Exch | 2004 |
The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
Topics: Adult; Anticonvulsants; Female; Follow-Up Studies; Humans; Male; Middle Aged; Seizures; Vigabatrin; | 2005 |
Design, synthesis and anticonvulsive activity of analogs of gamma-vinyl GABA.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Design; Isonipecotic Acids; Male; Mice; Nipec | 2004 |
Visual field constriction associated with vigabatrin: retinal nerve fiber layer photographic correlation.
Topics: Adolescent; Anticonvulsants; Humans; Male; Nerve Fibers; Photography; Retina; Seizures; Vigabatrin; | 2004 |
Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.
Topics: Adolescent; Anticonvulsants; Atrophy; Child; Electroretinography; Female; Humans; Infant; Male; Opti | 2004 |
Bilateral microinjections of vigabatrin in the central piriform cortex retard amygdala kindling in rats.
Topics: Amygdala; Animals; Anticonvulsants; Electrodes, Implanted; Female; GABA Agonists; gamma-Aminobutyric | 2004 |
Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Convulsants; Darkness; Light; Male; | 2005 |
Antiepileptic action induced by a combination of vigabatrin and tiagabine.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2005 |
Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dose-Respo | 2005 |
Differential effects of vigabatrin and zonisamide on the neuropeptide Y system in the hippocampus of seizure prone gerbil.
Topics: Animals; Anticonvulsants; Gerbillinae; Hippocampus; In Situ Hybridization; Isoxazoles; Neuropeptide | 2005 |
Evidence that GAD65 mediates increased GABA synthesis during intense neuronal activity in vivo.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Bicuculline; Blotting, Western; Dose-Respons | 2006 |
Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia.
Topics: Anticonvulsants; Disease Progression; Electroencephalography; Epilepsies, Myoclonic; Fatal Outcome; | 2006 |
Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Electroretinography; Follow- | 2006 |
Autistic regression associated with seizure onset in an infant with tuberous sclerosis.
Topics: Anticonvulsants; Autistic Disorder; Developmental Disabilities; Epilepsy; Humans; Infant; Male; Regr | 2006 |
Fetal exposure to GABA-acting antiepileptic drugs generates hippocampal and cortical dysplasias.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Female; Fetus | 2007 |
Study pharmacologic of the GABAergic and glutamatergic drugs on seizures and status epilepticus induced by pilocarpine in adult Wistar rats.
Topics: Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Ga | 2007 |
[Epileptic seizures in childhood: from seizure type to diagnosis].
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Diagnosis, Differential; Electroencephalography; Ep | 2008 |
Hypoxia-induced changes of seizure susceptibility in immature rats are modified by vigabatrin.
Topics: Animals; Anticonvulsants; Hypoxia, Brain; Male; Rats; Rats, Wistar; Seizures; Vigabatrin | 2007 |
Evidence implicating substantia nigra in regulation of kindled seizure threshold.
Topics: Aminocaproates; Amygdala; Animals; Behavior, Animal; Brain; Differential Threshold; Dose-Response Re | 1984 |
The amplification of the anticonvulsant effect of vinyl GABA (4-aminohexenoic acid) by esters of glycine.
Topics: 3-Mercaptopropionic Acid; Alcohols; Aminocaproates; Animals; Anticonvulsants; Drug Synergism; Glycin | 1984 |
Reversible suppression of amygdaloid kindled convulsion following unilateral gabaculine injection into the substantia innominata.
Topics: Action Potentials; Aminocaproates; Amygdala; Animals; Anticonvulsants; Basal Ganglia; Cyclohexanecar | 1984 |
Seizure protection and increased nerve-terminal GABA: delayed effects of GABA transaminase inhibition.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Aminooxyacetic Acid; Animals; Brain; Cell Compartmenta | 1980 |
Abortive amygdaloid kindled seizures following microinjection of gamma-vinyl-GABA in the vicinity of substantia nigra in rats.
Topics: Aminocaproates; Amygdala; Animals; Brain Mapping; Feedback; gamma-Aminobutyric Acid; Kindling, Neuro | 1983 |
Anticonvulsant action in mice with sound-induced seizures of the optical isomers of gamma-vinyl GABA.
Topics: 4-Aminobutyrate Transaminase; Acoustic Stimulation; Aminocaproates; Animals; Anticonvulsants; Body T | 1983 |
Cortical GABA turnover during bicuculline seizures in rats.
Topics: Aminocaproates; Animals; Bicuculline; Cerebral Cortex; gamma-Aminobutyric Acid; Male; Rats; Rats, In | 1983 |
Effects of gamma-acetylenic GABA and gamma-vinyl GABA on electrically-induced spinal cord convulsions and on spinal cord GABA concentration.
Topics: Alkynes; Aminocaproates; Animals; Electroshock; Female; gamma-Aminobutyric Acid; Rats; Seizures; Spi | 1980 |
Effect of gamma-vinyl GABA on bicuculline-induced seizures.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Bicuculline; Brain Chemistry | 1981 |
Pharmacological investigation of gamma aminobutyric acid (GABA) and the development of amygdala-kindled seizures in the rat.
Topics: 3-Mercaptopropionic Acid; 4-Aminobutyrate Transaminase; Aminocaproates; Amygdala; Animals; Bicuculli | 1981 |
Age-dependent effects of gamma-aminobutyric acid agents on flurothyl seizures.
Topics: Age Factors; Animals; Anticonvulsants; Baclofen; Convulsants; Flurothyl; GABA Agents; GABA Agonists; | 1995 |
Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency.
Topics: 4-Aminobutyrate Transaminase; Aldehyde Oxidoreductases; Brain Diseases, Metabolic; GABA Antagonists; | 1995 |
The significance of extracellular GABA in the substantia nigra of the rat during seizures and anticonvulsant treatments.
Topics: Animals; Anticonvulsants; gamma-Aminobutyric Acid; Male; Microdialysis; Pentylenetetrazole; Rats; Ra | 1995 |
4-Hydroxybutyric aciduria.
Topics: Adult; Anticonvulsants; Brain; Child; Child, Preschool; Dextromethorphan; Female; gamma-Aminobutyric | 1994 |
Further evidence of involvement of substantia nigra GABAB receptors in seizure suppression in developing rats.
Topics: Animals; Anticonvulsants; Convulsants; Flurothyl; GABA-B Receptor Antagonists; gamma-Aminobutyric Ac | 1994 |
Acute encephalopathy with vigabatrin.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Adult; Aminocaproates; Anticonvulsants; Carbamazepine; Com | 1993 |
Vigabatrin as an anticonvulsant against pentylenetetrazol seizures.
Topics: Aminocaproates; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Female; gamma-Aminobutyr | 1993 |
Vigabatrin in uncontrolled seizures: Belgian clinical experience. The Belgian Vigabatrin Evaluation Group.
Topics: Adolescent; Adult; Anticonvulsants; Belgium; Child; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Vigabatrin for refractory partial seizures in children with tuberous sclerosis.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; gamma-Aminobutyric Acid; Humans; Infant; Retro | 1994 |
The influence of thalamic GABA transmission on the susceptibility of adult rats to flurothyl induced seizures.
Topics: Aminocaproates; Animals; Anticonvulsants; Baclofen; Behavior, Animal; Bicuculline; Flurothyl; gamma- | 1993 |
Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Disease Models, A | 1995 |
Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA).
Topics: 4-Aminobutyrate Transaminase; Aldehyde Oxidoreductases; Child; Enzyme Inhibitors; gamma-Aminobutyric | 1996 |
Developmental regulation of regional functionality of substantial nigra GABAA receptors involved in seizures.
Topics: Acrylates; Animals; Bicuculline; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists; GABA-A R | 1996 |
EEG changes induced by vigabatrin monotherapy in focal epilepsy.
Topics: 4-Aminobutyrate Transaminase; Adult; Analysis of Variance; Anticonvulsants; Case-Control Studies; El | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Obstructive sleep apnoea following rapid weight gain secondary to treatment with vigabatrin (Sabril).
Topics: Adult; Anticonvulsants; Epilepsy; gamma-Aminobutyric Acid; Humans; Male; Seizures; Sleep Apnea Syndr | 1997 |
Vigabatrin: placental transfer in vivo and excretion into breast milk of the enantiomers.
Topics: Adult; Anticonvulsants; Central Nervous System; Female; Fetal Blood; gamma-Aminobutyric Acid; Humans | 1998 |
Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Animals; Anticonvulsants; Bicuculline; Cyclohexaneca | 1998 |
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cornea; Disease Models, Animal; Dizocilpine Malea | 1998 |
Behavioral effects of vigabatrin correlated with whole brain gamma-aminobutyric acid metabolism in audiogenic sensitive rats.
Topics: 4-Aminobutyrate Transaminase; Acoustic Stimulation; Animals; Anticonvulsants; Behavior, Animal; Brai | 1998 |
Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin.
Topics: Alanine Transaminase; Anticonvulsants; Diffuse Cerebral Sclerosis of Schilder; Enzyme Inhibitors; Fa | 1998 |
Mediodorsal thalamus plays a critical role in the development of limbic motor seizures.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Bicuculline; Brain Mapping; Carbon Radioisoto | 1998 |
Vigabatrin associated visual field constriction.
Topics: Anticonvulsants; Constriction, Pathologic; Electroretinography; Humans; Perceptual Disorders; Retina | 1999 |
Effects of vigabatrin on sleep-wakefulness cycle in amygdala-kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Circadian Rhythm; Dose-Response Relationship, Drug; Electric Sti | 2000 |
Single systemic dose of vigabatrin induces early proconvulsant and later anticonvulsant effect in rats.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2001 |
Vigabatrin directed against kindled seizures following cortical insult: impact on epileptogenesis and somatosensory recovery.
Topics: Animals; Anticonvulsants; Cerebral Cortex; Dose-Response Relationship, Drug; Electric Stimulation; E | 2001 |
Vigabatrin for startle-disease with altered cerebrospinal-fluid free gamma-aminobutyric acid.
Topics: 4-Aminobutyrate Transaminase; Adolescent; Aminocaproates; Anticonvulsants; Enzyme Inhibitors; Female | 1992 |
Is the anticonvulsant effect of substantia nigra infusion of gamma-vinyl-GABA (GVG) mediated by the GABAA receptor in rat pups?
Topics: Aminocaproates; Animals; Anticonvulsants; Bicuculline; Muscimol; Rats; Rats, Inbred Strains; Recepto | 1991 |
(4S)-4-amino-5,6-heptadienoic acid (MDL 72483): a potent anticonvulsant GABA-T inhibitor.
Topics: 3-Mercaptopropionic Acid; 4-Aminobutyrate Transaminase; Aminocaproates; Animals; Anticonvulsants; Fa | 1991 |
Effects of substantia nigra gamma-vinyl-GABA infusions on flurothyl seizures in adult rats.
Topics: Aminocaproates; Analysis of Variance; Animals; Anticonvulsants; Flurothyl; Infusions, Parenteral; Ma | 1991 |
Potentiation of gamma-vinyl GABA (vigabatrin) effects by glycine.
Topics: 3-Mercaptopropionic Acid; Acoustic Stimulation; Aminocaproates; Animals; Anticonvulsants; Drug Syner | 1990 |
Interaction between vigabatrin and phenytoin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Antipyrine; Blood Proteins; Drug Interactions; F | 1989 |
Cerebrospinal fluid GABA and seizure control with vigabatrin.
Topics: Adolescent; Adult; Aminocaproates; Anticonvulsants; Carnosine; Female; gamma-Aminobutyric Acid; Huma | 1989 |
Anticonvulsant action of intranigral gamma-vinyl-GABA: role of nonadrenergic neurotransmission.
Topics: Aminocaproates; Animals; Anticonvulsants; Dihydroxyphenylalanine; Dioxanes; Dioxins; Idazoxan; Musci | 1988 |
Role of the substantia nigra in GABA-mediated anticonvulsant actions.
Topics: Aminocaproates; Aminooxyacetic Acid; Animals; Anticonvulsants; Brain; Brain Diseases; Denervation; D | 1986 |
Microinjections of GABA agonists into the amygdala complex attenuates kindled seizure expression in the rat.
Topics: Aminocaproates; Amygdala; Animals; Behavior, Animal; Cerebral Cortex; gamma-Aminobutyric Acid; Kindl | 1988 |
Gamma-vinyl GABA: comparison of neurochemical and anticonvulsant effects in mice.
Topics: 4-Aminobutyrate Transaminase; Amino Acids; Aminocaproates; Animals; Anticonvulsants; Brain; gamma-Am | 1988 |
Functional anatomy of pentylenetetrazol and electroshock seizures in the rat brainstem.
Topics: Aminocaproates; Animals; Brain; Brain Mapping; Brain Stem; Electric Stimulation; Female; Hypothalamu | 1987 |
Anticonvulsant effects of GABA elevation in the deep prepiriform cortex.
Topics: Aminocaproates; Animals; Anticonvulsants; Bicuculline; Cerebral Cortex; gamma-Aminobutyric Acid; Mal | 1987 |
Anterior thalamic mediation of generalized pentylenetetrazol seizures.
Topics: Aminocaproates; Animals; Behavior, Animal; Bicuculline; Cerebral Cortex; Electroencephalography; Fem | 1986 |
Suppression of methionine sulfoximine seizures by intranigral gamma-vinyl GABA injection.
Topics: Aminocaproates; Animals; Anticonvulsants; Dose-Response Relationship, Drug; Injections; Male; Methio | 1987 |
Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma-vinyl-GABA into the substantia nigra.
Topics: Aminocaproates; Animals; Isoniazid; Male; Microinjections; Pilocarpine; Rats; Rats, Inbred Strains; | 1986 |
Anterior thalamus and substantia nigra: two distinct structures mediating experimental generalized seizures.
Topics: Aminocaproates; Animals; Electroshock; Female; Pentylenetetrazole; Rats; Rats, Inbred Strains; Seizu | 1986 |
GABAergic and dopaminergic systems of the substantia nigra and amygdaloid kindling in cats.
Topics: Aminocaproates; Amygdala; Animals; Cats; Differential Threshold; Dopamine; gamma-Aminobutyric Acid; | 1985 |
Effect of gamma-vinyl GABA on human pattern evoked visual potentials.
Topics: Adult; Aminocaproates; Evoked Potentials, Visual; Form Perception; Humans; Middle Aged; Pattern Reco | 1985 |